Case Reports:
Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report
PDF | Full Text | How to cite | Press Release
Metrics: PDF 330 views | Full Text 1240 views | ?
Abstract
Shreya Bhatia1, Manuel G. Cortez1, Spencer Lessans1 and Wade T. Iams1
1 Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA
Correspondence to:
Wade T. Iams, | email: | wade.t.iams@vumc.org |
Keywords:
Received: December 14, 2023 Accepted: December 28, 2023 Published: January 16, 2024
ABSTRACT
Osimertinib has been shown to be effective for patients with non-small cell lung cancer (NSCLC) with activating EGFR mutations, and these patients are at risk for leptomeningeal disease. In this report, we present a patient of East Asian descent whose initial presentation included severe, progressive leptomeningeal carcinomatosis and a small lung mass, with limited tissue available for molecular testing. She responded to empiric, urgent initiation of osimertinib, repeat tissue sampling revealed an EGFR L858R mutation, and she has experienced durable disease improvement for 18 months on osimertinib monotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28550